Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Flucelvax Quadrivalent in Adults
NCT01992094Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Jul 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) in influenza, sponsored by Novartis. Started Nov 2013; status: completed.
02
Drugs
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01992094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01992094.